|
|
||||||||

National Institute of Health, Tokyo, Japan
The incidence of viremia following vaccination with the 17D strain of yellow fever virus did not differ appreciably in a group of human subjects possessing prevaccination Japanese encephalitis neutralizing antibodies as a result of previous inapparent natural infection from the incidence of viremia in control groups possessing no prevaccination Group B arbor virus antibodies. There may have been a slight diminution in the level of circulating virus among the subjects with prevaccination JE neutralizing antibodies as compared with the level in the control groups; however, the number of uncontrolled factors which may have influenced these measurements precludes a firm conclusion on this matter.
* This work was carried out under Contract Number DA-49-007-MD-660 with the Office of the Surgeon General, Department of the Army, U.S. Department of Defense under the auspices of the Commission on Immunization of the Armed Forces Epidemiological Board.
Present address: Merck Institute for Research, West Point, Pennsylvania.
This article has been cited by other articles:
![]() |
N. KANESA-THASAN, W. SUN, G. V. LUDWIG, C. ROSSI, J. R. PUTNAK, J. A. MANGIAFICO, B. L. INNIS, and R. EDELMAN ATYPICAL ANTIBODY RESPONSES IN DENGUE VACCINE RECIPIENTS Am J Trop Med Hyg, December 1, 2003; 69(90060): 32 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Guirakhoo, J. Arroyo, K. V. Pugachev, C. Miller, Z.-X. Zhang, R. Weltzin, K. Georgakopoulos, J. Catalan, S. Ocran, K. Soike, et al. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine J. Virol., August 15, 2001; 75(16): 7290 - 7304. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |